Verinurad

Cat. No.: HY-16733

CAS No.: 1352792-74-5

Molecular Formula: $C_{20}H_{16}N_2O_2S$

Molecular Weight: 348.42

Target: URAT1

Pathway: Membrane Transporter/Ion Channel

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (287.01 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8701 mL	14.3505 mL	28.7010 mL
	5 mM	0.5740 mL	2.8701 mL	5.7402 mL
	10 mM	0.2870 mL	1.4350 mL	2.8701 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (7.18 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Verinurad (RDEA3170) is a highly potent and specific URAT1 inhibitor with an IC_{50} of 25 nM[1].

IC_{50} & Target

IC50: 25 nM (URAT1)[1]

In Vitro

Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC_{50} of 25 nM [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tan PK, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017 Apr 6;7(1):665.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA